Some of the activities of Medicala in Iran
Medikala Holding to promote the health and well-being of the country by relying on knowledge and expertise and working with international active healthcare companies in health field attempts to apply world-class standards to provide a distinct service in the field of medical and pharmaceutical products.
The main focus of Medicala Holding activities is the import, sale and after-sales service of a variety of medical products, such as heart stent that is one of the essential and strategic goods of the country.
Commitment to such obligations as goods quality, massive and dynamic sales system, and the provision of after-sales service to customers are among the general principles of this holding.
Medicala Holding has more than 2 years of experience specializing in the import of top brands of heart stent.
Medicala Holding has a brilliant record in reengineering the marketing and sales system and cooperation with the official representatives of the Boston Scinite and Medtronic and etc. companies in Iran and with unique policies; it has been able to multiply sales volumes and has been introduced in the market as a well-known brand.
Percentage of progress in infrastructure development
History of Coronary Stents
Since the introduction of percutaneous transluminal coronary angioplasty (PTCA) by Gruntzig in 1977, major advancements have been made in the clinical practice of percutaneous coronary intervention (PCI). Puel and Sigwart, in 1986, deployed the first coronary stent to act as a scaffold, thus 1) preventing vessel closure during PTCA, and 2) reducing the incidence of angiographic restenosis, which had an occurrence rate of 30-40%. By 1999, stenting composed 84.2% of all PCIs. Despite the widespread use of these devices, bare metal stents (BMS) have been associated with a 20-30% restenosis rate requiring reintervention. Restenosis occurs as a result of neointimal hyperplasia—growth of scar tissue within the stent—due to the proliferation and migration of vascular smooth muscle cells. This phenomenon is clinically evident within the first 6-9 months after stent placement, and occurs in response to strut-associated injury and inflammation.
In 2001, drug-eluting stents (DES) were introduced as a strategy to minimize restenosis and requirement for reintervention. The currently available polymer-coated stents contain antiproliferative agents which elute locally in the implanted coronary artery to prevent neointimal hyperplasia. Initial animal studies demonstrated a clear benefit over BMS (4-6% restenosis versus 20-30%), and early clinical trials further supported this. In addition, at 2-year follow-up using both angiography and ultrasound, the clinical safety of DES was further established with minimal late lumen loss observed. A recent pooled analysis demonstrated a 74% reduction in the risk of target lesion revascularization for both sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) compared to BMS. At present, 90% of all stents placed in the United States and Europe are DES.